Fertility Center PPC Advertising Agency

The paid media problem in fertility is a measurement problem before it is a media problem. Published estimates put a single IVF cycle at roughly $15,000 to $25,000 including medication, and per-patient revenue across a treatment relationship spanning testing, multiple cycles, transfers, and later siblings at $40,000 to $80,000. Against that, an acquisition cost that would be indefensible for a dentist is trivially justified. But the same reporting describes two to four consultations per started cycle, which means a cost per lead figure tells you almost nothing about whether the money worked. Add the restrictions, since reproductive health is a sensitive category where remarketing and personalized targeting are unavailable, and you have a channel that is expensive per click, forgiving on lifetime value, unable to recover lost visitors, and impossible to judge at the top of the funnel. Getting the allocation right requires measuring further down than most accounts ever look.

1The Economics That Permit Patience

Fertility has among the most forgiving acquisition economics in healthcare, and clinics routinely underspend because they benchmark against the wrong comparison.

The relationship is rarely a single transaction. A patient may begin with testing, attempt IUI, move to IVF, undergo more than one cycle, return for a frozen embryo transfer, and come back years later for a sibling. Published estimates put the resulting per-patient revenue at $40,000 to $80,000 across that span, with lifetime value ranges reported anywhere from $5,000 for a single-consultation patient to $50,000 or more for a multi-cycle one.

That has a specific consequence. A more expensive consultation from a high-trust channel routinely beats a cheap click that never converts, because the cost difference is small relative to what a converted patient is worth. Clinics that optimise hard on cost per click in this vertical are managing the least important variable available to them.

It also means patience is rational. The lag between first contact and a started cycle can run months, and an account judged on thirty days will be turned off before it has demonstrated anything.

2Reported Benchmarks and Why They Disagree

Published figures in this vertical vary widely and the variation is instructive rather than confusing.

The spread in cost per lead is largely definitional. If a newsletter signup counts as a lead your figure looks excellent and your consultation rate looks poor. If only a consultation request counts, the number multiplies and reflects something real. Establish what your own account counts before comparing yourself to anything.

The organic figure is the one that should shape strategy. If content-driven leads genuinely cost a fraction of paid ones, and organic reportedly accounts for around half of fertility clinic traffic, then paid is a supplement to an organic base rather than the foundation.

3The Available Channel Set

Reproductive health restrictions narrow the options and each remaining channel does a distinct job.

• Non-branded search. The core. High intent, high cost, and the channel most directly tied to consultation volume.
• Branded search. Disproportionately valuable here, because it catches the person who researched in spring and searched your name in autumn. This is your permitted substitute for retargeting, and competitors will bid on your name.
• Physician name campaigns. Frequently overlooked. Patients and referrers search individual reproductive endocrinologists.
• Local and map visibility. Supporting rather than leading, given patients travel for this specialty.
• Educational social. Awareness and seminar registration, measured on branded search lift rather than direct booking.
• Owned channels. Email and phone follow-up after consent, doing the nurture work retargeting cannot.

Professional audience channels are worth evaluating for referral development rather than patient acquisition, since reaching OB-GYNs and primary care physicians is a genuine objective in this specialty and reported healthcare costs on professional platforms compare reasonably.

4Allocating Across Service Lines

Fertility centres sell services with very different economics and very different regulatory surfaces, and blending them produces an account optimised toward whatever converts fastest.

Egg freezing deserves particular attention as an allocation decision, because it acquires a patient years before their highest-value treatment and at a lower acquisition cost. Clinics that treat it as a side service are undervaluing the pipeline it builds.

5Spending Against Clinical Capacity

Capacity in a fertility centre is constrained in ways that are unusually rigid, and budget should be set against them.

The constraints are physician consultation slots, laboratory and embryology capacity, retrieval and transfer scheduling, and nursing coordination load. Laboratory capacity in particular is a hard ceiling that cannot be expanded quickly, and a practice generating more cycle starts than its embryology team can safely handle has created a clinical risk rather than a growth outcome.

Watch time to first available consultation as your budget signal. In a category where patients are already anxious about time, a long wait sends them elsewhere, and you paid for the enquiry regardless.

When capacity binds, the productive responses are improving consultation attendance and conversion from existing volume, shifting toward services with different capacity profiles such as evaluation or egg freezing, or investing in retention and referral rather than acquisition. Increasing spend into a full calendar produces waiting lists and poor reviews.

6Tracking Within Privacy Boundaries

Reproductive health information is among the most sensitive data that exists, and the default marketing measurement setup is not automatically appropriate.

The specific question is third-party tags on pages where patients book, complete intake, or access records. That creates a data flow requiring review, and the decision belongs to your privacy officer or counsel rather than to a media team.

1. Settle the boundary first. Then design measurement inside it rather than retrofitting.
2. Instrument general content normally where appropriate. An article about egg freezing is a different situation from an intake form.
3. Use call tracking with a sensible duration threshold. Sixty seconds filters misdials without capturing content.
4. Keep patient-level analysis in your own systems. Run it there, act on the conclusions manually.
5. Maintain a tag inventory. Reviewed whenever anything is added.

Accept lower resolution as the correct trade. The metrics that matter most, consultations attended and cycles started, come from your practice systems anyway.

7Compliance Risk in Paid Media

Two risks sit above performance and both need active management.

Platform risk is the smaller one. Disapprovals in a restricted category are normal, and the practices that keep them from escalating are reading the cited policy rather than guessing, fixing rather than resubmitting, and treating an accumulating rejection pattern as a signal.

Professional risk is the larger one. SART reviews member clinics' advertising materials and websites, membership can be affected, and that status appears in the CDC's federally mandated annual report. An ad or landing page presenting success rates outside the guidelines is therefore a professional exposure, not merely a marketing error.

Our working position is that outcome data does not appear in ad copy, that landing pages carrying success rates are built to the guideline structure, and that your medical director signs off on outcome presentation rather than your marketing team. That is a slower process and it is the correct one.

8How We Rebalance

Monthly review, quarterly judgement, because the decision cycle is too long for monthly conclusions to be reliable.

Each month we look at cost per booked consultation and cost per attended consultation by channel and service line, consultation to cycle conversion where the practice can supply it, time to first available appointment, any policy or guideline events, and capacity across consultation, laboratory, and procedure scheduling.

Moves should be modest and directional. Because a patient acquired in March may start a cycle in July, aggressive monthly reallocation acts on incomplete data and frequently reverses decisions that were working.

The genuine strategic reviews happen quarterly, with a full look at cohort behaviour. That is where you can see whether a channel is producing patients who actually proceed to treatment, which is the only question that ultimately matters.

9What Reporting Should Show

Reporting has to reach past the ad platform or it will describe a channel that looks nothing like the business.

Show spend, enquiries, consultations booked, consultations attended, and cycles started where available, by channel and service line. Show branded and non-branded separately, since branded performs the recovery function retargeting would elsewhere and blending it overstates acquisition efficiency. Show time to first available consultation alongside spend, since those two numbers explain each other.

Add cohort views quarterly, tracking patients acquired in a period through to treatment, because that is where the long cycle becomes visible and where channel quality separates from channel volume.

Then finish with a recommendation in a sentence. Where the next dollar goes and why.

For general platform mechanics rather than this vertical's constraints, our Google Ads guide covers campaign types, bidding, and structure.